Table 1.
Baseline characteristics and comparison of the study patients in the AC and AR treatment arms.
Table 2.
Univariate and multivariate analysis of recurrence and death.
Fig 1.
Kaplan-Meier survival curves indicating no significant differences in the progression-free survival or overall survival outcomes between patients who received adjuvant chemotherapy (AC, n = 85) and those who received adjuvant radiotherapy or concurrent chemoradiation therapy (AR, n = 177) (p = 0.47 and 0.13, respectively).
AC: adjuvant chemotherapy; AR: adjuvant radiotherapy of concurrent chemoradiation.
Table 3.
Baseline characteristics and comparison of patients in the AC and AR treatment arms from the nodal metastasis subgroup (n = 107).
Table 4.
Univariate and multivariate analysis of recurrence and death in patients with a nodal metastasis.
Fig 2.
In the nodal metastasis subgroup, Kaplan-Meier survival curves also indicated no significant differences in progression-free survival or overall survival between patients radiotherapy or concurrent chemoradiation therapy (AR, n = 80) (p = 0.69 and 0.49, respectively).
AC: adjuvant chemotherapy; AR: adjuvant radiotherapy of concurrent chemoradiation.
Table 5.
Comparison of recurrence between the AC and AR treatment arms by the Cox proportional hazard model using the inverse-probability-of-treatment weighting method.
Fig 3.
Salvage treatment and final status of the recurred patients (n = 39).
AC: adjuvant chemotherapy; AR: adjuvant radiotherapy of concurrent chemoradiation; CCRT: concurrent chemoradiation; DOD: die of disease; NED: no evidence of disease; F/U: follow-up; AWD: alive with disease.
Table 6.
Adverse effects of adjuvant treatment.